A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCC
Phase 4
Completed
- Conditions
- Hepatitis B Associated Hepatocellular Carcinoma
- Registration Number
- NCT01263002
- Lead Sponsor
- Bukwang Pharmaceutical
- Brief Summary
An open study to evaluate the Efficacy, Safety of Clevudine monotherapy or Adefovir and Clevudine combination in Proportion to Roadmap Concept in patients with chronic hepatitis B Associated Hepatocellular Carcinoma
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 33
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Proportion of patients with HBV DNA levels < 60 IU/mL 48 week
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Clevudine's antiviral activity in HBV-associated hepatocellular carcinoma?
How does the combination of Adefovir and Clevudine compare to standard-of-care treatments for chronic hepatitis B in HCC patients?
Which biomarkers are associated with response to Clevudine monotherapy in HBV-related hepatocellular carcinoma?
What are the potential adverse events of Clevudine and Adefovir combination therapy in chronic hepatitis B patients with HCC?
Are there alternative antiviral compounds or combination strategies to Clevudine for managing HBV-associated hepatocellular carcinoma?
Trial Locations
- Locations (1)
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital🇰🇷Seoul, Korea, Republic of